Mr. Tullman brings more than 25 years of biopharmaceutical global commercialization and drug development experience. Mr. Tullman also serves as the co-founder and Managing Partner for NeXeption, LLC, and co-founder and Chairman of Aclaris Therapeutics. He was Chairman and Chief Executive Officer of Ceptaris Therapeutics (acquired by Actelion 2013), co-founder Chairman of Vicept Therapeutics (acquired by Allergan 2011), co-founder President and CEO of Ception Therapeutics, (acquired by Cephalon 2010), co-founder Trigenesis Therapeutics, a dermatology company (acquired by Reddy’s Laboratories 2004). He also served on the Board of Directors for Euromed, a wound care company. Mr. Tullman started his career at SmithKline Beecham and held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman earned a B.S. from Rutgers University in New Jersey.